Unfortunately, researchers notice that aberrant expressions of some cancer-associated genes contribute to DDP-resistance in ccRCC treatment, and targeting the corresponding genes, including CIP2A [30], SMYD2 [28], and PARK7 [27], improve DDP-sensitivity in ccRCC cells. The gene discussed is SMYD2; the disease is nonpapillary renal cell carcinoma.